SVRE vs CELU

For growth investors, Celularity Inc.

(CELU) is the stronger pick with 138. 1% revenue growth year-over-year, versus -38. 1% for SaverOne 2014 Ltd (SVRE). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Celularity Inc.

(CELU) delivered a total return of -99. 1%, compared to -100. 0% for SaverOne 2014 Ltd (SVRE). Over 10 years, the gap is even starker: CELU returned -99. 1% versus SVRE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SaverOne 2014 Ltd (SVRE) is the lower-risk stock at 1.

17β versus Celularity Inc. 's 1. 42β — meaning CELU is approximately 22% more volatile than SVRE relative to the S&P 500. On balance sheet safety, SaverOne 2014 Ltd (SVRE) carries a lower debt/equity ratio of 70% versus 8% for Celularity Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Celularity Inc.

(CELU) is pulling ahead at 138. 1% versus -38. 1% for SaverOne 2014 Ltd (SVRE). On earnings-per-share growth, the picture is similar: Celularity Inc. grew EPS 76. 0% year-over-year, compared to 72. 2% for SaverOne 2014 Ltd. Over a 3-year CAGR, SVRE leads at 55. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Celularity Inc.

(CELU) is the more profitable company, earning -106. 8% net margin versus -20. 8% for SaverOne 2014 Ltd — meaning it keeps -106. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CELU leads at -70. 7% versus -1975. 8% for SVRE. At the gross margin level — before operating expenses — CELU leads at 72. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, SaverOne 2014 Ltd (SVRE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

17)). Both have compounded well over 10 years (SVRE: -100. 0%, CELU: -99. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SVRE (Technology) and CELU (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SVRE is a small-cap quality compounder stock; CELU is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.